Generic Partners Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Generic Partners Pty Limited Pharmaceutical Import Records from India — 3 Products, $3.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Generic Partners Pty Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $3.4M Trade | TransData Nexus

Generic Partners Pty Limited

Pharmaceutical Importer · Australia · Nutritional Supplements Focus · $3.4M Total Trade · DGFT Verified

Generic Partners Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $3.4M across 3 products in 3 therapeutic categories. Based on 115 verified import shipments from Indian Customs (DGFT) records, Generic Partners Pty Limited is the #1 buyer in 1 product including Melatonin. Generic Partners Pty Limited sources from 5 verified Indian suppliers, with Gracure Pharmaceuticals Limited accounting for 68.5% of imports.

Generic Partners Pty Limited — Import Portfolio & Supplier Network

Generic Partners Pty Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Generic Partners Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gracure Pharmaceuticals Limited	$1.1M	43	68.5%
Rpg Life Sciences Limited	$333.8K	9	21.1%
Piramal Pharma Limited

What Formulations Does Generic Partners Pty Limited Import?

Formulation	Value	Ships
Apo health osteo relief paracetamol	$209.2K	6
Chemists own osteo relief paracetamol	$147.1K	5
Apo sodium valproate 500 MG	$100.0K	2
Apo health osteo relief paracetamol 665MG 100s/btl paracetamol modified release tablets 665 MG	$91.1K	2
Chemists own melatonin sleep aid	$62.5K	2
401223002 vzole tablets 200 MG 8	$50.0K	1
Apo-sodium valproate 500 tablets	$50.0K	1
Apo azathioprine 50 MG	$50.0K	1
Apo health osteo relief paracetamol 665MG 100s/ btlparacetamol modified release tablets 665MG	$50.0K	1
Quetia xr 400 quetiapine fumarate	$47.0K	2
Pro-banthine 15MG tablets	$46.1K	1
Apo-sodium valproate 200 tablets	$44.5K	1
Dinasane dienogest 2MG tablet b.no.	$43.4K	1
Apo meloxicam 15MG capsules meloxicam capsules 15 MG	$34.6K	1
Melatonin arxmelatonin 2 MG modifiedrelease tablets2x2x15/pacb.no.at230690aat230692a manufacturing	$33.0K	1

Generic Partners Pty Limited imports 40 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Melatonin	Nutritional Supplements	$2.3M	76	19.9%	1
2	Meloxicam	Analgesics & Antipyretics	$843.8K	32	0.4%	7
3	Azathioprine	Immunosuppressants	$301.0K	7	0.9%	18

Generic Partners Pty Limited imports 3 pharmaceutical products across 3 categories into Australia totaling $3.4M. The company is the #1 buyer for 1 product: Melatonin.

Generic Partners Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Generic Partners Pty Limited is an Australian pharmaceutical importer specializing in the acquisition and distribution of finished pharmaceutical formulations. The company operates as a buyer, sourcing a diverse range of pharmaceutical products from international suppliers to meet the needs of the Australian market. While specific details about its headquarters and parent company are not publicly disclosed, Generic Partners Pty Limited plays a significant role in the Australian pharmaceutical distribution network, ensuring the availability of various therapeutic goods to healthcare providers and consumers across the country.

2Distribution Network

The distribution network of Generic Partners Pty Limited encompasses multiple warehouse locations strategically positioned to facilitate efficient logistics and timely delivery of pharmaceutical products throughout Australia. The company's logistics capabilities are designed to handle a diverse product portfolio, ensuring compliance with Australian regulations and maintaining the integrity of pharmaceutical goods during transit. While specific geographic coverage details are not publicly available, the company's operations are structured to serve the entire Australian market effectively.

3Industry Role

In Australia's pharmaceutical supply chain, Generic Partners Pty Limited functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from international suppliers, including those in India, and supplies these products to various stakeholders within the Australian healthcare system. By importing a range of therapeutic goods, Generic Partners Pty Limited contributes to the diversity and availability of pharmaceutical products in the Australian market, catering to the needs of healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Generic Partners Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Generic Partners Pty Limited exhibits a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from a select group of suppliers. Notably, the company has imported approximately $1.1 million worth of products from GRACURE PHARMACEUTICALS LIMITED, accounting for 43 shipments and representing 68.5% of its total imports from India. This concentration suggests a strategic choice to establish strong partnerships with key suppliers, potentially leading to favorable terms and consistent product quality. However, such dependency also introduces risks; any disruptions in the supply chain from these primary suppliers could impact Generic Partners Pty Limited's ability to meet market demand. The company's reliance on a limited number of suppliers indicates the importance of maintaining robust relationships and monitoring supplier stability to mitigate potential risks.

2Supply Chain Resilience

The resilience of Generic Partners Pty Limited's Indian supply chain is influenced by its reliance on a limited number of suppliers. While this focus can lead to streamlined operations and potentially better pricing, it also means that the company may face challenges if any of these suppliers encounter operational issues, regulatory changes, or other disruptions. The company's import data indicates a diverse range of formulations, with 40 unique products imported, which may help mitigate some risks associated with supplier concentration. However, the overall resilience of the supply chain would depend on the company's ability to diversify its supplier base, establish contingency plans, and ensure compliance with Australian regulatory standards to maintain a steady supply of pharmaceutical products.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of pharmaceutical imports is overseen by the Therapeutic Goods Administration (TGA), a division of the Department of Health and Aged Care. The TGA is responsible for ensuring that therapeutic goods, including medicines, medical devices, and biologicals, meet appropriate standards for quality, safety, and efficacy before they can be supplied in Australia. The primary legislation governing these activities is the Therapeutic Goods Act 1989, which establishes the regulatory framework for the import, export, manufacture, and supply of therapeutic goods in Australia. Under this Act, therapeutic goods must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported into, supplied in, or exported from Australia. This process ensures that all therapeutic goods available in the Australian market have been evaluated and authorized by the TGA, providing assurance of their safety and efficacy to consumers and healthcare providers.

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must comply with the requirements set forth by the TGA. This includes obtaining market authorization for each product, which involves demonstrating that the goods meet Australian standards for quality, safety, and efficacy. Manufacturers of these goods must hold Good Manufacturing Practice (GMP) certificates recognized by the TGA. The TGA accepts GMP certifications from various international regulatory bodies, including the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers possess valid GMP certifications from these recognized authorities to facilitate the importation process. Additionally, importers must obtain wholesale distribution authorization from the TGA, which involves meeting specific requirements related to storage, handling, and distribution to ensure the integrity and quality of the therapeutic goods throughout the supply chain.

Generic Partners Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Generic Partners Pty Limited's product category focus on nutritional supplements, analgesics and antipyretics, and immunosuppressants aligns with prevalent health concerns and market demand in Australia. Nutritional supplements, comprising 66.8% of imports, cater to the growing consumer interest in health and wellness. Analgesics and antipyretics, accounting for 24.5%, address widespread needs for pain relief and fever management. Immunosuppressants, representing 8.7%, are critical for patients requiring immune system modulation, such as those undergoing organ transplants or managing autoimmune disorders. This strategic focus enables Generic Partners Pty Limited to meet diverse therapeutic needs and capitalize on significant market segments within the Australian pharmaceutical landscape.

2Sourcing Profile

Generic Partners Pty Limited's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. The company's preference for finished products over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market goods that can be directly supplied to the Australian market. By sourcing from India, Generic Partners Pty Limited leverages cost advantages and a wide range of available formulations, ensuring a diverse product portfolio. This approach allows the company to efficiently meet the demands of the Australian healthcare system while maintaining compliance with regulatory standards.

Seller's Guide — How to Become a Supplier to Generic Partners Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Generic Partners Pty Limited, particularly if they can offer competitive pricing, consistent product quality, and reliable supply chains. The company's current sourcing pattern, with a high concentration on a few key suppliers, suggests potential gaps that new entrants could fill. By providing alternative sources for the products currently imported from existing suppliers, new Indian exporters can position themselves as valuable partners to Generic Partners Pty Limited. Establishing strong relationships and demonstrating the ability to meet Australian regulatory standards will be crucial for these exporters to

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Generic Partners Pty Limited

What products does Generic Partners Pty Limited import from India?

Generic Partners Pty Limited imports 3 pharmaceutical products across 3 categories. Top imports: Melatonin ($2.3M), Meloxicam ($843.8K), Azathioprine ($301.0K).

Who supplies pharmaceuticals to Generic Partners Pty Limited from India?

Generic Partners Pty Limited sources from 5 verified Indian suppliers. The primary supplier is Gracure Pharmaceuticals Limited (68.5% of imports, $1.1M).

What is Generic Partners Pty Limited's total pharmaceutical import value?

Generic Partners Pty Limited's total pharmaceutical import value from India is $3.4M, based on 115 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Generic Partners Pty Limited focus on?

Generic Partners Pty Limited imports across 3 categories. The largest: Nutritional Supplements (66.8%), Analgesics & Antipyretics (24.5%), Immunosuppressants (8.7%).

Get Full Generic Partners Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.